Preclinical Data Highlights Potential Application for Novel Mechanism Drug Candidate in Pediatric Cancers
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 06/01/09 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster presentation summarizing non-clinical
data for GSK-923295, a novel inhibitor of centromere-associated protein E
(CENP-E), was presented at the 2009 Annual Meeting of the American Society
of Clinical Oncology (ASCO) held from May 29 - June 2, 2009 in Orlando, FL.
The poster summarizes an evaluation of GSK-923295 in pediatric preclinical
cancer xenograft models and highlights possible opportunities for
exploration of this novel mechanism in pediatric cancers.
"These data relating to GSK-923295 are encouraging for the future potential
of this novel mechanism in the treatment of pediatric patients with certain
cancers," stated David J. Morgans, Jr., PhD, Cytokinetics' Executive Vice
President, Preclinical Research and Development. "The findings in these
preclinical models point to areas for possible exploration in further human
clinical testing following the completion of the ongoing Phase I clinical
trial designed to explore the safety and tolerability profile of GSK-923295
in adult cancer patients."
Moderated Poster Discussion at ASCO
A poster titled, "Pediatric Preclinical Testing Program (PPTP) Testing of
the CENP-E Inhibitor: GSK923295A" was presented on Monday, June 1, 2009
and moderated by Malcolm A. Smith, MD, PhD, Associate Branch Chief for
Pediatric Oncology, Cancer Therapy Evaluation Program, National Cancer
Institute, Bethesda, MD. This poster summarized preclinical testing of
GSK-923295, an inhibitor of CENP-E, in pediatric preclinical xenograft
models. The authors concluded that GSK-923295 potently inhibited growth of
the PPTP cell lines, with a complete cytotoxic effect most obvious for the
acute lymphoblastic leukemia (ALL) cell lines. GSK-923295 showed high
level in vivo activity against many of the PPTP xenografts across multiple
tumor histologies, with the most consistent activity noted in the Ewing
sarcoma and rhabdoid tumor panels. The pattern of response to GSK-923295
shows similarity to that observed in the kinesin spindle protein (KSP)
inhibitor ispinesib. The observed high level of activity for GSK-923295 in
pediatric xenograft models will need to be evaluated in the context of
systemic exposures achieved in the xenograft models and those achievable in
humans at tolerable doses. GSK-923295 is currently the subject of an
ongoing Phase I clinical trial in adult patients with solid tumors.
Pediatric clinical evaluation is planned following completion of this Phase
I clinical trial.
Development Status of GSK-923295
In October 2008, GlaxoSmithKline (GSK) reported interim data from a Phase I
dose-escalation and pharmacokinetic study of GSK-923295 in adult patients
with solid tumors.
